Bookmark and Share
BioAssay: AID 1771

qHTS Assay for Inhibitors of CDC-like Kinase 4 (ADP-Glo Assay)

Clk4 (Invitrogen, cat# PV3839) was assayed using ATP and the RS repeat peptide (AnaSpec cat # 61722) as substrates. In the assay, the ADP levels were detected using Promega ADP-Glo technology wherein the remaining ATP from the kinase reaction is first depleted with an ATPase reagent followed by a reagent that contains and enzyme which converts the ADP produced to ATP as well as Ultra-Glo more ..
_
   
 Tested Compounds
 Tested Compounds
All(1352)
 
 
Active(356)
 
 
Inactive(747)
 
 
Inconclusive(249)
 
 
 Tested Substances
 Tested Substances
All(1352)
 
 
Active(356)
 
 
Inactive(747)
 
 
Inconclusive(249)
 
 
AID: 1771
Data Source: NCGC (CLK576)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2009-05-18
Modify Date: 2009-05-27

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 356
Related Experiments
Show more
AIDNameTypeProbeComment
1379Counterscreen for Luciferase (Kinase-Glo TM) InhibitionConfirmatory depositor-specified cross reference
1795qHTS Assay for Inhibitors of CDC-like Kinase 4 (ADP-FP Assay)Confirmatory depositor-specified cross reference
1969Confirmaiton Assay for Inhibitors of CDC-like Kinase 4 (ADP-Glo Assay)Confirmatory depositor-specified cross reference
1983Confirmation Assay for Inhibitors of CDC-like Kinase 4 (ADP-FP Assay)Confirmatory depositor-specified cross reference
1997qHTS for Inhibitors of CDC-like Kinase 4: SummarySummary3 depositor-specified cross reference
1770qHTS Assay for Inhibitors of CDC-like Kinase 4 (Kinase-Glo Assay)Confirmatory same project related to Summary assay
1970Confirmation Assay for Inhibitors of CDC-like Kinase 4 (Kinase-Glo Assay)Confirmatory same project related to Summary assay
2705Assay for Inhibitors of Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (Kinase-Glo assay)Confirmatory same project related to Summary assay
2710Kinase Inhibition Profile Study on Inhibitors of CDC-like Kinase 4Other same project related to Summary assay
493204Confirmation Assay for Inhibitors of CDC-like Kinase 4 (Kinase-Glo Assay): SAR round 2Confirmatory same project related to Summary assay
493206Assay for Inhibitors of Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (Kinase-Glo assay): round 2 SARConfirmatory same project related to Summary assay
504421Kinase Inhibition Study on Inhibitors of CDC-like Kinase 4 (Reaction Biology data): SAR round 2Confirmatory same project related to Summary assay
504424Kinase Inhibition Study on Inhibitors of Dyrk1a (Reaction Biology data)Confirmatory same project related to Summary assay
504427Kinase Inhibition Study on Inhibitors of CDC-like Kinase 2 (Reaction Biology data)Confirmatory same project related to Summary assay
504428Kinase Inhibition Study on Inhibitors of CDC-like Kinase 3 (Reaction Biology data)Confirmatory same project related to Summary assay
504429Kinase Inhibition Study on Inhibitors of Dyrk1b (Reaction Biology data)Confirmatory same project related to Summary assay
504430Kinase Inhibition Study on Inhibitors of CDC-like Kinase 1 (Reaction Biology data)Confirmatory same project related to Summary assay
504534Secondary Assay for Inhibitors of Human Cdc-like kinase 4 (Clk4): HEK-293 Cell Viability AssayConfirmatory same project related to Summary assay
624034Reaction Biology data for inhibitors of CLK4: Probe SARConfirmatory same project related to Summary assay
624045Reaction Biology data for inhibitors of DYRK1A: Probe SARConfirmatory same project related to Summary assay
624046Reaction Biology data for inhibitors of DYRK1B: Probe SARConfirmatory same project related to Summary assay
624047Reaction Biology data for inhibitors of CLK1: Probe SARConfirmatory same project related to Summary assay
624048Reaction Biology data for inhibitors of CLK2: Probe SARConfirmatory same project related to Summary assay
624049Reaction Biology data for inhibitors of CLK3: Probe SARConfirmatory same project related to Summary assay
624093Confirmation Assay for Inhibitors of Dyrk1a (Kinase-Glo Assay): KU probeConfirmatory same project related to Summary assay
624094Confirmation Assay for Inhibitors of Clk4 (Kinase-Glo Assay): KU probeConfirmatory same project related to Summary assay
Description:
NIH Molecular Libraries Probe Production Centers Network [MLPCN]
NIH Chemical Genomics Center [NCGC]
MLPCN Grant: 1R03MH084827-01
Assay Submitter (PI): Tom Misteli

NCGC Assay Overview:
Clk4 (Invitrogen, cat# PV3839) was assayed using ATP and the RS repeat peptide (AnaSpec cat # 61722) as substrates. In the assay, the ADP levels were detected using Promega ADP-Glo technology wherein the remaining ATP from the kinase reaction is first depleted with an ATPase reagent followed by a reagent that contains and enzyme which converts the ADP produced to ATP as well as Ultra-Glo luciferase and D-luciferin which generates a bioluminescence signal from the ATP. The positive control for the assay was TG003 (Sigma-Aldrich, cat# 300801-52-9) which has been described as an inhibitor of Clk 4[1].
Protocol
NCGC Assay Protocol Summary:
Two uL/well of substrate-buffer solution (100 uM RS peptide, 1 uM ATP, 1x ADP-Glo Buffer A, 2 mM MgCl2, 0.5 mM EGTA, 2.5 mM DTT, 0.01% Triton X-100, final concentrations) was dispensed into 1536-well plates (Greiner, solid white, medium binding assay plates) with the Aurora Discovery BioRAPTR Flying Reagent Dispenser (FRD; Beckton-Dickenson). Twenty-three nanoliter of compound and control solutions were transferred to the assay plate using a Kalypsys pin-tool followed by 0.5 uL/well Clk4-buffer solution (25 nM Clk4, 1x ADP-Glo Buffer A, 2 mM MgCl2, 0.5 mM EGTA, 2.5 mM DTT, 0.01% Triton X-100 final concentration) dispensing for a total kinase reaction volume of 2.5 uL/ well. After 1 hr of room-temperature incubation, 2.5 uL ADP-Glo reagent was added and incubated at room temperature for 45 min to stop the kinetic reaction and degrade residual ATP. The ADP product was then converted to ATP by adding 5 uL per well of ADP-Glo Reagent II to yield a total assay volume of 10 uL/ well. Luminescence was detected after 30 min room temperature incubation with the Perkin Elmer Viewlux.
Comment
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
3. Compounds that interfere with the Ultra-Glo luciferase could interfere with this assay. PubChem AID: 1379 can be used as counter-screen for this [2].
Categorized Comment - additional comments and annotations
From ChEMBL:
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1PhenotypeIndicates type of activity observed: inhibitor, activator, fluorescent, cytotoxic, inactive, or inconclusive.String
2Potency*Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.FloatμM
3EfficacyMaximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.Float%
4Analysis CommentAnnotation/notes on a particular compound's data or its analysis.String
5Curve_DescriptionA description of dose-response curve quality. A complete curve has two observed asymptotes; a partial curve may not have attained its second asymptote at the highest concentration tested. High efficacy curves exhibit efficacy greater than 80% of control. Partial efficacies are statistically significant, but below 80% of control.String
6Fit_LogAC50The logarithm of the AC50 from a fit of the data to the Hill equation (calculated based on Molar Units).Float
7Fit_HillSlopeThe Hill slope from a fit of the data to the Hill equation.Float
8Fit_R2R^2 fit value of the curve. Closer to 1.0 equates to better Hill equation fit.Float
9Fit_InfiniteActivityThe asymptotic efficacy from a fit of the data to the Hill equation.Float%
10Fit_ZeroActivityEfficacy at zero concentration of compound from a fit of the data to the Hill equation.Float%
11Fit_CurveClassNumerical encoding of curve description for the fitted Hill equation.Float
12Excluded_PointsWhich dose-response titration points were excluded from analysis based on outlier analysis. Each number represents whether a titration point was (1) or was not (0) excluded, for the titration series going from smallest to highest compound concentrations.String
13Max_ResponseMaximum activity observed for compound (usually at highest concentration tested).Float%
14Activity at 0.00512 uM (0.00512μM**)% Activity at given concentration.Float%
15Activity at 0.026 uM (0.0256μM**)% Activity at given concentration.Float%
16Activity at 0.128 uM (0.128μM**)% Activity at given concentration.Float%
17Activity at 0.640 uM (0.64μM**)% Activity at given concentration.Float%
18Activity at 3.200 uM (3.2μM**)% Activity at given concentration.Float%
19Activity at 16.00 uM (16μM**)% Activity at given concentration.Float%
20Activity at 80.00 uM (80μM**)% Activity at given concentration.Float%
21Compound QCNCGC designation for data stage: 'qHTS', 'qHTS Verification', 'Secondary Profiling'String

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1R03MH084827-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: